EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The interplay between heart failure and chronic kidney disease

Anuradha Lala iD, Adeera Levin iD, Kamlesh Khunti iD

Diabetes, Obesity and Metabolism · 2025-07 · 27 (7) · 3568-3582

DOI: 10.1111/dom.16371 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 21.04.2025. Verfasst von Anuradha Lala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Health Science, Icahn School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Heart Failure, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer AG, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) and heart failure (HF) are two globally prevalent, independent, long‐term conditions, which often coexist in an individual and display a bidirectional yet interconnected relationship. The presence of CKD often leads to the development of HF and vice versa, which propagates the worsening of each disease, reflecting an intertwined disease cycle. Both HF and CKD share common risk factors, such as increasing age, diabetes, high blood pressure, obesity and smoking. Data show that approximately half of all people with HF also have CKD, which impacts patient burden and quality of life due to a significantly greater risk of hospitalization and death, compared with those that have either CKD or HF. To maximize treatment effectiveness in individuals with both HF and CKD, healthcare professionals should recognize that these two diseases are systemic conditions, representing organ‐specific manifestations of similar underlying processes. It is also essential to understand the role of renin–angiotensin system inhibitors, sodium–glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon‐like peptide‐1 receptor agonists in managing these conditions. Lifestyle modifications should also be recommended. This review discusses factors contributing to the interplay between HF and CKD and the key role of healthcare professionals in providing appropriate treatment for the co‐existing diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureRenal Insufficiency, ChronicHumansRisk FactorsSodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsQuality of Life

Stichwörter der Autor:innen

SGLT2 inhibitorcardiovascular diseaseheart failureprimary care

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department of Population Health Science, Icahn School of Medicine, New York, New York, USA.
  • Division of Nephrology, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
  • Diabetes Research Centre, University of Leicester, Leicester, UK.

ORCID-Profile: Anuradha Lala, Adeera Levin, Kamlesh Khunti

Förderung

  • Bayer AG
  • Bayer

Zitieren

APA

Lala, A., Levin, A., & Khunti, K. (2025). The interplay between heart failure and chronic kidney disease. Diabetes, Obesity and Metabolism, 27(7), 3568-3582. https://doi.org/10.1111/dom.16371

Vancouver

Lala A, Levin A, Khunti K. The interplay between heart failure and chronic kidney disease. Diabetes, Obesity and Metabolism. 2025;27(7):3568-3582. doi:10.1111/dom.16371

BibTeX
@article{Lala2025,
  author = {Lala, Anuradha and Levin, Adeera and Khunti, Kamlesh},
  title = {The interplay between heart failure and chronic kidney disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {7},
  pages = {3568--3582},
  doi = {10.1111/dom.16371}
}
Kostenlos starten →